As mentioned previously, patients suffering from Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations had strikingly poor responses to PD-1 based immunotherapies compared to those with wt EGFR [29,30,31]. Here, EGFR is linked to non-small cell lung carcinoma.